Who is sponsoring NCT05693701?

NCT05693701 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT05693701?

Interventions in NCT05693701: Implementation Strategy Bundle, Usual care notification.

What condition does NCT05693701 study?

NCT05693701 studies Lipid Metabolism Disorder.

Is NCT05693701 still recruiting?

NCT05693701 is currently recruiting now. Last updated 17 March 2026.

Last reviewed 2026-03-17 · How we verify

NCT05693701: DONATE-FH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicomponent Intervention Study- Blood Donors With High Cholesterol

Recruiting now NA Last updated 17 March 2026

What this trial tests

NA trial testing Implementation Strategy Bundle in Lipid Metabolism Disorder in 100 participants. Currently enrolling.

Timeline

27 February 2023

Primary endpoint
30 April 2027

30 April 2027

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	100
Start date	27 February 2023
Primary completion	30 April 2027
Estimated completion	30 April 2027
Sites	1 location across United States

Drugs / interventions tested

Implementation Strategy Bundle
Usual care notification

Conditions studied

Lipid Metabolism Disorder — all drugs for Lipid Metabolism Disorder →

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 18 to 75, any sex, with Lipid Metabolism Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose and objective of this study is to improve cholesterol treatment among blood donors with FH (Familial Hypercholesterolemia).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05693701 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 17 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05693701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing